US BROKER MOVES: IP upgraded at JPM; XOM downgraded at BofA

UPGRADES

Bancolombia (CIB) Upgraded to Buy from Neutral at Goldman Sachs; PT USD 98 (prev USD 81)
Gossamer Bio (GOSS) Upgraded to Outperform from Market Perform at Leerink; PT USD 1
Honeywell (HON) Upgraded to Neutral from Underperform at BofA Securities; PT USD 265 (prev USD 205)
International Paper (IP) Upgraded to Overweight from Neutral at JPMorgan; PT USD 61 (prev USD 51)
Medtronic (MDT) Upgraded to Buy from Neutral at UBS; PT USD 100
Magnolia Oil & Gas (MGY) Upgraded to Buy from Hold at Truist Securities; PT USD 33
Nutrien (NTR) Upgraded to Outperform from Neutral at BNP Paribas Exane; PT USD 80
Richardson Electronics (RELL) Upgraded to Outperform from Market Perform at Northland; PT USD 24
Solventum (SOLV) Upgraded to Buy from Neutral at UBS; PT USD 95

DOWNGRADES

Albertsons (ACI) Downgraded to Neutral from Buy at UBS; PT USD 12 (prev USD 20)
Bank of Marin Bancorp (BMRC) Downgraded to Neutral from Buy at Brean Capital
Capricor Therapeutics (CAPR) Downgraded to Neutral from Buy at Alliance Global Partners
Clorox (CLX) Downgraded to Hold from Buy at Jefferies; PT USD 98 (prev USD 125)
Crinetics Pharmaceuticals (CRNX) Downgraded to Neutral from Buy at UBS; PT USD 85 (prev USD 55)
Eastern Bankshares (EBC) Downgraded to Equal Weight from Overweight at Stephens
Forte Biosciences (FBRX) Downgraded to Equal Weight from Overweight at Barclays; PT USD 77 (prev USD 74)
Fresenius Medical Care (FMS) Downgraded to Underperform from Neutral at BNP Paribas Exane; PT USD 19.90
Intuit (INTU) Downgraded to Hold from Buy at TD Cowen; PT USD 304 (prev USD 504)
Levi Strauss (LEVI) Downgraded to Equal Weight from Overweight at Wells Fargo; PT USD 25
Progyny (PGNY) Downgraded to Equal Weight from Overweight at Barclays; PT USD 34 (prev USD 27)
Alpine Income Property Trust (PINE) Downgraded to Outperform from Strong Buy at Raymond James; PT USD 22
Procept BioRobotics (PRCT) Downgraded to Neutral from Buy at UBS
RXO (RXO) Downgraded to Sell from Hold at TD Cowen; PT USD 19 (prev USD 24)
Selective Insurance Group (SIGI) Downgraded to Market Perform from Outperform at BMO Capital; PT USD 97
Exxon Mobil (XOM) Downgraded to Neutral from Buy at BofA Securities; PT USD 158 (prev USD 154)

INITIATIONS

Alphatec Holdings (ATEC) Initiated Buy at UBS; PT USD 15
Anterix (ATEX) Initiated Buy at Clear Street; PT USD 161
Becton Dickinson (BDX) Initiated Buy at UBS; PT USD 190
Bausch + Lomb (BLCO) Initiated Buy at UBS
Benitec Biopharma (BNTC) Initiated Outperform at Wedbush; PT USD 16
Cooper Companies (COO) Initiated Neutral at UBS; PT USD 75
Edwards Lifesciences (EW) Initiated Buy at UBS; PT USD 110
Glaukos (GKOS) Initiated Neutral at UBS
Globus Medical (GMED) Initiated Neutral at UBS; PT USD 82
GXO Logistics (GXO) Initiated Overweight at Wells Fargo; PT USD 18
Integra LifeSciences (IART) Initiated Neutral at UBS; PT USD 19
Inspire Medical Systems (INSP) Initiated Sell at UBS; PT USD 39
Intuitive Surgical (ISRG) Initiated Buy at UBS; PT USD 500
Kodiak Gas Services (KGS) Initiated Overweight at Piper Sandler; PT USD 78
Insulet (PODD) Initiated Neutral at UBS; PT USD 174
Silvergate Capital (SI) Initiated Buy at UBS; PT USD 27
SI-BONE (SIBN) Initiated Buy at UBS; PT USD 24
STAAR Surgical (STAA) Initiated Sell at UBS; PT USD 20
STERIS (STE) Initiated Buy at UBS; PT USD 275
Stryker (SYK) Initiated Buy at UBS; PT USD 400
Tenax Therapeutics (TENX) Initiated Buy at Canaccord; PT USD 35
Teleflex (TFX) Initiated Neutral at UBS; PT USD 145
TransMedics Group (TMDX) Initiated Neutral at UBS; PT USD 80
Zimmer Biomet (ZBH) Initiated Buy at UBS

Daily broker roundups of this kind are routine tape-filler; single-name rating changes have historically moved prices modestly and transiently, with the follow-through concentrated in the first session and fading unless the call reflects a genuine change in the consensus rather than a house rotation. The more substantive signal here is the UBS initiation sweep across medical technology, a sector-wide launch that reads as the bank standing up or refreshing coverage; initiations of this scale tend to embed a house view on procedure volumes and hospital capital spending, and the spread between its Buy and Sell calls within the group marks where the bank sees the cycle differentiating. The Exxon downgrade to Neutral with a raised target is the familiar pattern of a rating cut driven by valuation catch-up rather than deteriorating fundamentals, which has typically produced less price pressure than a cut accompanied by estimate reductions. The Intuit downgrade with a sharply lower target is the opposite case, a thesis change, and historically those carry more weight. Worth noting is whether any of these calls cluster into a theme, energy and staples appearing on the downgrade side alongside cyclical upgrades has on previous occasions signalled desks repositioning for a shift in the macro backdrop rather than idiosyncratic views.